Selected research
Industry Research
Neuropeptide Y Receptor Industry Research Report 2026
Market perspective
The global Neuropeptide Y Receptor market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Neuropeptide Y Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Neuropeptide Y Receptor is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Neuropeptide Y Receptor is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Neuropeptide Y Receptor include Gila Therapeutics, Novo Nordisk, XL-protein, Lilly Eli, Novartis, Pfizer, Merck & Co, Mannkind and Gilead Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Neuropeptide Y Receptor market in terms of revenue (US$ million) and, where applicable, sales volume (t), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/t) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Neuropeptide Y Receptor Market by Company
Gila Therapeutics
Novo Nordisk
XL-protein
Lilly Eli
Novartis
Pfizer
Merck & Co
Mannkind
Gilead Sciences
Genentech
Neuropeptide Y Receptor Segment by Type
Food Grade
Pharmaceutical Grade
Neuropeptide Y Receptor Segment by Application
Medicine
Food Additives
Others
Neuropeptide Y Receptor Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuropeptide Y Receptor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuropeptide Y Receptor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuropeptide Y Receptor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Neuropeptide Y Receptor manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Neuropeptide Y Receptor by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Neuropeptide Y Receptor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Food Grade
- Pharmaceutical Grade
Applications
- Medicine
- Food Additives
- Others
Companies covered
- Gila Therapeutics
- Novo Nordisk
- XL-protein
- Lilly Eli
- Novartis
- Pfizer
- Merck & Co
- Mannkind
- Gilead Sciences
- Genentech
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Neuropeptide Y Receptor Market Size (2021-2032)
- 2.2.2 Global Neuropeptide Y Receptor Sales (2021-2032)
- 2.2.3 Global Neuropeptide Y Receptor Market Average Price (2021-2032)
- 2.3 Neuropeptide Y Receptor by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Food Grade
- 2.3.3 Pharmaceutical Grade
- 2.4 Neuropeptide Y Receptor by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Medicine
- 2.4.3 Food Additives
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Neuropeptide Y Receptor Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Neuropeptide Y Receptor Sales (t) of Manufacturers (2021-2026)
- 3.3 Global Neuropeptide Y Receptor Revenue of Manufacturers (2021-2026)
- 3.4 Global Neuropeptide Y Receptor Average Price by Manufacturers (2021-2026)
- 3.5 Global Neuropeptide Y Receptor Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Neuropeptide Y Receptor, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Neuropeptide Y Receptor, Product Type & Application
- 3.8 Global Manufacturers of Neuropeptide Y Receptor, Established Date
- 3.9 Global Neuropeptide Y Receptor Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Gila Therapeutics
- 4.1.1 Gila Therapeutics Company Information
- 4.1.2 Gila Therapeutics Business Overview
- 4.1.3 Gila Therapeutics Neuropeptide Y Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Gila Therapeutics Neuropeptide Y Receptor Product Portfolio
- 4.1.5 Gila Therapeutics Recent Developments
- 4.2 Novo Nordisk
- 4.2.1 Novo Nordisk Company Information
- 4.2.2 Novo Nordisk Business Overview
- 4.2.3 Novo Nordisk Neuropeptide Y Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novo Nordisk Neuropeptide Y Receptor Product Portfolio
- 4.2.5 Novo Nordisk Recent Developments
- 4.3 XL-protein
- 4.3.1 XL-protein Company Information
- 4.3.2 XL-protein Business Overview
- 4.3.3 XL-protein Neuropeptide Y Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 XL-protein Neuropeptide Y Receptor Product Portfolio
- 4.3.5 XL-protein Recent Developments
- 4.4 Lilly Eli
- 4.4.1 Lilly Eli Company Information
- 4.4.2 Lilly Eli Business Overview
- 4.4.3 Lilly Eli Neuropeptide Y Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Lilly Eli Neuropeptide Y Receptor Product Portfolio
- 4.4.5 Lilly Eli Recent Developments
- 4.5 Novartis
- 4.5.1 Novartis Company Information
- 4.5.2 Novartis Business Overview
- 4.5.3 Novartis Neuropeptide Y Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novartis Neuropeptide Y Receptor Product Portfolio
- 4.5.5 Novartis Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Neuropeptide Y Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Neuropeptide Y Receptor Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 Merck & Co
- 4.7.1 Merck & Co Company Information
- 4.7.2 Merck & Co Business Overview
- 4.7.3 Merck & Co Neuropeptide Y Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Merck & Co Neuropeptide Y Receptor Product Portfolio
- 4.7.5 Merck & Co Recent Developments
- 4.8 Mannkind
- 4.8.1 Mannkind Company Information
- 4.8.2 Mannkind Business Overview
- 4.8.3 Mannkind Neuropeptide Y Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Mannkind Neuropeptide Y Receptor Product Portfolio
- 4.8.5 Mannkind Recent Developments
- 4.9 Gilead Sciences
- 4.9.1 Gilead Sciences Company Information
- 4.9.2 Gilead Sciences Business Overview
- 4.9.3 Gilead Sciences Neuropeptide Y Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Gilead Sciences Neuropeptide Y Receptor Product Portfolio
- 4.9.5 Gilead Sciences Recent Developments
- 4.10 Genentech
- 4.10.1 Genentech Company Information
- 4.10.2 Genentech Business Overview
- 4.10.3 Genentech Neuropeptide Y Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Genentech Neuropeptide Y Receptor Product Portfolio
- 4.10.5 Genentech Recent Developments
5 Global Neuropeptide Y Receptor Market Scenario by Region
- 5.1 Global Neuropeptide Y Receptor Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Neuropeptide Y Receptor Sales by Region: 2021-2032
- 5.2.1 Global Neuropeptide Y Receptor Sales by Region: 2021-2026
- 5.2.2 Global Neuropeptide Y Receptor Sales by Region: 2027-2032
- 5.3 Global Neuropeptide Y Receptor Revenue by Region: 2021-2032
- 5.3.1 Global Neuropeptide Y Receptor Revenue by Region: 2021-2026
- 5.3.2 Global Neuropeptide Y Receptor Revenue by Region: 2027-2032
- 5.4 North America Neuropeptide Y Receptor Market Facts & Figures by Country
- 5.4.1 North America Neuropeptide Y Receptor Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Neuropeptide Y Receptor Sales by Country (2021-2032)
- 5.4.3 North America Neuropeptide Y Receptor Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Neuropeptide Y Receptor Market Facts & Figures by Country
- 5.5.1 Europe Neuropeptide Y Receptor Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Neuropeptide Y Receptor Sales by Country (2021-2032)
- 5.5.3 Europe Neuropeptide Y Receptor Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Neuropeptide Y Receptor Market Facts & Figures by Country
- 5.6.1 Asia Pacific Neuropeptide Y Receptor Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Neuropeptide Y Receptor Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Neuropeptide Y Receptor Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Neuropeptide Y Receptor Market Facts & Figures by Country
- 5.7.1 South America Neuropeptide Y Receptor Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Neuropeptide Y Receptor Sales by Country (2021-2032)
- 5.7.3 South America Neuropeptide Y Receptor Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Neuropeptide Y Receptor Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Neuropeptide Y Receptor Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Neuropeptide Y Receptor Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Neuropeptide Y Receptor Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Neuropeptide Y Receptor Sales by Type (2021-2032)
- 6.1.1 Global Neuropeptide Y Receptor Sales by Type (2021-2032) & (t)
- 6.1.2 Global Neuropeptide Y Receptor Sales Market Share by Type (2021-2032)
- 6.2 Global Neuropeptide Y Receptor Revenue by Type (2021-2032)
- 6.2.1 Global Neuropeptide Y Receptor Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Neuropeptide Y Receptor Revenue Market Share by Type (2021-2032)
- 6.3 Global Neuropeptide Y Receptor Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Neuropeptide Y Receptor Sales by Application (2021-2032)
- 7.1.1 Global Neuropeptide Y Receptor Sales by Application (2021-2032) & (t)
- 7.1.2 Global Neuropeptide Y Receptor Sales Market Share by Application (2021-2032)
- 7.2 Global Neuropeptide Y Receptor Revenue by Application (2021-2032)
- 7.2.1 Global Neuropeptide Y Receptor Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Neuropeptide Y Receptor Revenue Market Share by Application (2021-2032)
- 7.3 Global Neuropeptide Y Receptor Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Neuropeptide Y Receptor Value Chain Analysis
- 8.1.1 Neuropeptide Y Receptor Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Neuropeptide Y Receptor Production Mode & Process
- 8.2 Neuropeptide Y Receptor Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Neuropeptide Y Receptor Distributors
- 8.2.3 Neuropeptide Y Receptor Customers
9 Global Neuropeptide Y Receptor Analyzing Market Dynamics
- 9.1 Neuropeptide Y Receptor Industry Trends
- 9.2 Neuropeptide Y Receptor Industry Drivers
- 9.3 Neuropeptide Y Receptor Industry Opportunities and Challenges
- 9.4 Neuropeptide Y Receptor Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst